Serum NGAL as a Predictor of Clinical and Endoscopic Activity of Inflammatory Bowel Disease
NCT ID: NCT05151458
Last Updated: 2021-12-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
80 participants
OBSERVATIONAL
2021-12-29
2022-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development of Novel Fecal Microbial Biomarkers for Inflammatory Bowel Disease
NCT05598489
Serologic Markers for Inflammatory Bowel Disease During Clinical Forms With Weak or Strong Evolution Capacities
NCT01216514
NKT Role in the Regulation of the Inflammatory Bowel Disease
NCT02884557
Role of C-Reactive Protein /Albumin Ratio in Evaluation of Disease Activity in Patients With Inflammatory Bowel Disease
NCT05738915
Artificial Intelligence System Based on Raman Spectroscopy in Inflammatory Bowel Disease
NCT04888299
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
15 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohamed Alsadek Mahmoud Ghozaly
Serum NGAL as a predictor of clinical and endoscopic activity of inflammatory bowel disease
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Hossam Ma Abd Alwahab
Role: CONTACT
References
Explore related publications, articles, or registry entries linked to this study.
Oikonomou KA, Kapsoritakis AN, Theodoridou C, Karangelis D, Germenis A, Stefanidis I, Potamianos SP. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol. 2012 May;47(5):519-30. doi: 10.1007/s00535-011-0516-5. Epub 2011 Dec 27.
Nakov R. New markers in ulcerative colitis. Clin Chim Acta. 2019 Oct;497:141-146. doi: 10.1016/j.cca.2019.07.033. Epub 2019 Jul 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NGAL in IBD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.